Treatment of DIC is centered on treating the underlying condition. Transfusions of platelets or fresh frozen plasma can be considered in cases of significant bleeding, or those with a planned invasive procedure. The target goal of such transfusion depends on the clinical situation. Cryoprecipitate can be considered in those with a low fibrinogen level. Treatment of thrombosis with anticoagulants such as heparin is rarely used due to the risk of bleeding. Recombinant human activated protein C was previously recommended in those with severe sepsis and DIC, but drotrecogin alfa has been shown to confer no benefit and was withdrawn from the market in 2011. Recombinant factor VII has been proposed as a "last resort" in those with severe hemorrhage due to obstetric or other causes, but conclusions about its use are still insufficient.
complications of HELLP syndrome
symptom of HELLP syndrome
complications of Hemolytic–uremic syndrome
medical cause of Rhabdomyolysis
complications of Hepatitis
complications of Hemolysis
complications of Hemolytic disease of the newborn
complications of Eclampsia